Payment overview · 2025
General Payments
$752.11
32 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Kevin Rowe, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOUNT VERNON, KY · NPI 1649298779
Verified facts
What the public records show
CMS Open Payments records show Michael Kevin Rowe, MD received $752.11 in general payments during 2025 across 32 reported records.
Axsome Therapeutics, Inc. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Farxiga, Rexulti, Trelegy Ellipta, Xhance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Auvelity by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trelegy Ellipta by this doctor in 2024.
Optinose US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xhance as an associated drug or biological on 10863 records involving 5058 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xhance by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $211.13 | 28.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.77 | 21.1% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $157.07 | 20.9% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $64.87 | 8.6% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $43.99 | 5.8% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $43.63 | 5.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.33 | 4.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.53 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.79 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $752.11 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $211.13 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $157.07 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.62 | 5 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $64.87 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.15 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.15 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 75 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 106 | exact normalized | Medicare Part D |
| Xhance xhance |
2025 | Xhance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
114 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| Optinose US, Inc. Exact reporting entity; no affiliate inference |
2025 | Xhance open payments reported associated product |
CMS Open Payments — General Payments 10863 supporting records · 5058 recipient NPIs · example record 1163252000 |
Xhance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 759 | 177 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 752 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 526 | 121 |
| Ramipril | Ramipril | 521 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 510 | 103 |
| Montelukast Sodium | Montelukast Sodium | 447 | 89 |
| Gabapentin | Gabapentin | 421 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 110 |
| Fluticasone Propionate | Fluticasone Propionate | 391 | 132 |
| Lisinopril | Lisinopril | 391 | 97 |
| Amitriptyline Hcl | Amitriptyline Hcl | 348 | 69 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 346 | 95 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 345 | 47 |
| Chlorthalidone | Chlorthalidone | 343 | 82 |
| Furosemide | Furosemide | 316 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 307 | 102 |
| Omeprazole | Omeprazole | 307 | 74 |
| Famotidine | Famotidine | 297 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 292 | 76 |
| Ondansetron Odt | Ondansetron | 284 | 89 |
| Bupropion Xl | Bupropion Hcl | 268 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 63 |
| Sertraline Hcl | Sertraline Hcl | 256 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 249 | 48 |
| Ozempic | Semaglutide | 244 | 51 |
| Pregabalin | Pregabalin | 244 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 232 | 56 |
| Clonidine Hcl | Clonidine Hcl | 218 | 74 |
| Metformin Hcl | Metformin Hcl | 218 | 56 |
| Potassium Chloride | Potassium Chloride | 196 | 83 |
| Ibuprofen | Ibuprofen | 184 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 44 |
| Buspirone Hcl | Buspirone Hcl | 178 | 36 |
| Tramadol Hcl | Tramadol Hcl | 175 | 51 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 160 | 39 |
| Irbesartan | Irbesartan | 156 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 41 |
| Mounjaro | Tirzepatide | 142 | 36 |
| Ezetimibe | Ezetimibe | 140 | 36 |
| Eliquis | Apixaban | 139 | 34 |
| Carvedilol | Carvedilol | 136 | 37 |
| Labetalol Hcl | Labetalol Hcl | 136 | 32 |
| Jardiance | Empagliflozin | 135 | 30 |
| Meloxicam | Meloxicam | 129 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 129 | 45 |
| Trazodone Hcl | Trazodone Hcl | 128 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 127 | 40 |
| Fenofibrate | Fenofibrate | 115 | 26 |
| Linzess | Linaclotide | 114 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 29 |
| Baclofen | Baclofen | 112 | 19 |
| Metformin Hcl Er | Metformin Hcl | 112 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 20 |
| Methocarbamol | Methocarbamol | 107 | 37 |
| Aripiprazole | Aripiprazole | 106 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 106 | 25 |
| Allopurinol | Allopurinol | 105 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 102 | 18 |
| Mirtazapine | Mirtazapine | 100 | 28 |
| Alendronate Sodium | Alendronate Sodium | 99 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 95 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 18 |
| Meclizine Hcl | Meclizine Hcl | 91 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 23 |
| Nitroglycerin | Nitroglycerin | 83 | 36 |
| Farxiga | Dapagliflozin Propanediol | 78 | 21 |
| Cefdinir | Cefdinir | 77 | 67 |
| Finasteride | Finasteride | 77 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 14 |
| Rexulti | Brexpiprazole | 75 | 13 |
| Simvastatin | Simvastatin | 75 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 20 |
| Doxepin Hcl | Doxepin Hcl | 70 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 18 |
| Azithromycin | Azithromycin | 68 | 52 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 30 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 65 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 64 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 20 |
| Donepezil Hcl | Donepezil Hcl | 62 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 15 |
| Losartan Potassium | Losartan Potassium | 62 | 31 |
| Myrbetriq | Mirabegron | 62 | 12 |
| Colchicine | Colchicine | 58 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 58 | 15 |
| Celecoxib | Celecoxib | 57 | 15 |
| Clonazepam | Clonazepam | 57 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 13 |
| Endocet | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 11 |
| Valsartan | Valsartan | 54 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 53 | 14 |
| Midodrine Hcl | Midodrine Hcl | 53 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 19 |
| Januvia | Sitagliptin Phosphate | 52 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 51 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Belsomra | Suvorexant | 49 | 17 |
| Sucralfate | Sucralfate | 49 | 17 |
| Entresto | Sacubitril/Valsartan | 48 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Xtampza Er | Oxycodone Myristate | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 14 |
| Prednisone | Prednisone | 42 | 16 |
| Digoxin | Digoxin | 40 | suppressed |
| Lactulose | Lactulose | 39 | 12 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 37 | 11 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Kerendia | Finerenone | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 12 |
| Valacyclovir | Valacyclovir Hcl | 33 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 11 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | 11 |
| Atomoxetine Hcl | Atomoxetine Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Leqvio | Inclisiran Sodium | 24 | 12 |
| Nystatin | Nystatin | 24 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Veozah | Fezolinetant | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 20 |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Buprenorphine | Buprenorphine | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Prolia | Denosumab | 18 | 15 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | 14 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Verquvo | Vericiguat | 16 | suppressed |
| Xhance | Fluticasone Propionate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Relistor | Methylnaltrexone Bromide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Nisoldipine | Nisoldipine | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $752.11 · 32 records | Axsome Therapeutics, Inc. | Auvelity, BREZTRI, FARXIGA, Ohtuvayre, Prolastin-C Liquid, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Xhance | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error